Karyopharm Therapeutics Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
85 WELLS AVENUE, NEWTON, MA, 02459
Mailing Address
85 WELLS AVENUE, NEWTON, MA, 02459
Phone
617-658-0600
Fiscal Year End
1231
EIN
263931704
Financial Overview
FY2025
-$76.42M
Net Income
$164.42M
Total Assets
$401.34M
Total Liabilities
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 27, 2026 | View on SEC |
| 8-K Current report of material events | March 24, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
| 8-K Current report of material events | March 3, 2026 | View on SEC |
| 4 Insider stock transaction report | March 3, 2026 | View on SEC |
| 8-K Current report of material events | February 19, 2026 | View on SEC |
Annual Reports
10-K
February 13, 2026
- Commercial-stage biopharmaceutical company with flagship product XPOVIO® approved for multiple myeloma and diffuse large B-cell lymphoma.
- Robust commercial activity, significant pipeline progression, and active financial management including non-dilutive financing.
Material Events
8-K
Strategy Change
March 24, 2026
High Impact
- Phase 3 SENTRY trial met primary endpoint of spleen volume reduction
- Secured $30 million in immediate private funding with potential for $44 million more
8-K
Financial Distress
March 3, 2026
High Impact
- Conditional lifeline provides temporary reprieve and delays debt payments.
- Opportunity to focus on crucial Phase 3 XPOVIO trial for endometrial cancer.
Insider Trading
SELL
7 insiders
10 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.